Top-Rated StocksTop-RatedNASDAQ:UTHR United Therapeutics (UTHR) Stock Price, News & Analysis → Kiss of death from Joe Biden (From Porter & Company) (Ad) Free UTHR Stock Alerts $275.13 +4.68 (+1.73%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$268.65▼$275.5350-Day Range$228.26▼$276.5052-Week Range$204.44▼$279.98Volume1.14 million shsAverage Volume460,863 shsMarket Capitalization$12.20 billionP/E Ratio13.01Dividend YieldN/APrice Target$309.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get United Therapeutics alerts: Email Address United Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside12.5% Upside$309.44 Price TargetShort InterestBearish9.14% of Float Sold ShortDividend StrengthN/ASustainability-2.00Upright™ Environmental ScoreNews Sentiment0.77Based on 11 Articles This WeekInsider TradingSelling Shares$39.02 M Sold Last QuarterProj. Earnings Growth9.71%From $24.61 to $27.00 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.78 out of 5 starsMedical Sector43rd out of 924 stocksPharmaceutical Preparations Industry14th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageUnited Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about United Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.14% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in United Therapeutics has recently decreased by 2.08%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnited Therapeutics has received a 71.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Antihypertensives (C02)" and "Cancer medication (L01)" products. See details.Environmental SustainabilityThe Environmental Impact score for United Therapeutics is -2.00. Previous Next 2.7 News and Social Media Coverage News SentimentUnited Therapeutics has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for United Therapeutics this week, compared to 7 articles on an average week.Search InterestOnly 5 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat Follows4 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,021,745.00 in company stock.Percentage Held by Insiders12.50% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about United Therapeutics' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for United Therapeutics are expected to grow by 9.71% in the coming year, from $24.61 to $27.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 13.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.77.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 13.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.34.Price to Earnings Growth RatioUnited Therapeutics has a PEG Ratio of 4.09. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about United Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About United Therapeutics Stock (NASDAQ:UTHR)United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Read More UTHR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UTHR Stock News HeadlinesJune 1 at 4:56 AM | insidertrades.comMartine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockMay 29, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Martine A. Rothblatt Sells 3,600 SharesMay 23, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Sells $404,947.80 in StockMay 21, 2024 | insidertrades.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) Director Sells 3,600 Shares of StockMay 16, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Christopher Patusky Sells 1,310 SharesMay 15, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $955,728.00 in StockMay 11, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 SharesMay 8, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $934,920.00 in StockMay 7, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Christopher Causey Sells 2,240 SharesMay 4, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $929,124.00 in StockJune 2 at 10:27 AM | seekingalpha.comUnited Therapeutics: Exciting Company With A Big ProblemMay 29, 2024 | benzinga.comUnited Therapeutics Stock (NASDAQ:UTHR), Quotes and News SummaryMay 29, 2024 | finance.yahoo.comInvesting in United Therapeutics (NASDAQ:UTHR) five years ago would have delivered you a 213% gainMay 24, 2024 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Martine A. Rothblatt Sells 1,468 SharesMay 24, 2024 | americanbankingnews.comStockNews.com Lowers United Therapeutics (NASDAQ:UTHR) to BuyMay 20, 2024 | investorplace.com7 Biotech Stocks That Could Breathe New Life Into Your PortfolioMay 16, 2024 | gurufocus.comInsider Sale: CFO and Treasurer James Edgemond Sells 40,160 Shares of United Therapeutics Corp ...May 15, 2024 | seekingalpha.comMannKind Outperforms As Tyvaso DPI Captures Market ShareMay 15, 2024 | finance.yahoo.comQ1 2024 Liquidia Corp Earnings CallMay 9, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Arcus Biosciences (RCUS)May 7, 2024 | finance.yahoo.comInsider Sale: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR)May 7, 2024 | finance.yahoo.comInsider Sale: Director Judy Olian Sells Shares of United Therapeutics Corp (UTHR)May 6, 2024 | investorplace.com3 Biotech Stocks to Double Your Money in the Next 24 MonthsMay 2, 2024 | markets.businessinsider.comBuy Rating on United Therapeutics: Strong Market Position and Growth Potential Despite New CompetitorsMay 2, 2024 | finance.yahoo.comUnited Therapeutics Corp (UTHR) Q1 2024 Earnings Call Transcript Highlights: Record Revenue and ...See More Headlines Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today6/02/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees1,168Year Founded1996Price Target and Rating Average Stock Price Target$309.44 High Stock Price Target$400.00 Low Stock Price Target$240.00 Potential Upside/Downside+12.5%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$21.15 Trailing P/E Ratio13.01 Forward P/E Ratio11.18 P/E Growth4.09Net Income$984.80 million Net Margins42.05% Pretax Margin55.28% Return on Equity18.72% Return on Assets15.35% Debt Debt-to-Equity Ratio0.04 Current Ratio3.77 Quick Ratio3.64 Sales & Book Value Annual Sales$2.33 billion Price / Sales5.24 Cash Flow$22.08 per share Price / Cash Flow12.46 Book Value$120.35 per share Price / Book2.29Miscellaneous Outstanding Shares44,360,000Free Float38,812,000Market Cap$12.20 billion OptionableOptionable Beta0.54 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Martine A. Rothblatt J.D. (Age 69)M.B.A., Ph.D., Founder, Chairman & CEO Comp: $5.32MMr. Michael I. Benkowitz (Age 52)President & COO Comp: $2.83MMr. James C. Edgemond (Age 56)CFO & Treasurer Comp: $2.01MMr. Paul A. Mahon J.D. (Age 60)Executive VP, General Counsel & Corporate Secretary Comp: $2.31MMr. Dewey Steadman C.F.A.Head of Investor RelationsMs. Holly HobsonAssociate Vice President of Human ResourcesKevin T. GraySenior Vice President of Strategic Operations & LogisticsMr. Patrick Poisson (Age 56)Executive VP of Technical Operations Dr. Leigh PetersonExecutive Vice President of Product Development & XenotransplantationMr. Gil GoldenSenior VP & Chief Medical OfficerMore ExecutivesKey CompetitorsBlueprint MedicinesNASDAQ:BPMCReata PharmaceuticalsNASDAQ:RETATeva Pharmaceutical IndustriesNYSE:TEVABridgeBio PharmaNASDAQ:BBIOPerrigoNYSE:PRGOView All CompetitorsInsiders & InstitutionsMartine A RothblattSold 3,600 sharesTotal: $968,616.00 ($269.06/share)Farallon Capital Management LLCSold 366,000 shares on 5/24/2024Ownership: 0.248%Cetera Advisors LLCBought 2,068 shares on 5/24/2024Ownership: 0.005%Martine A RothblattSold 3,600 sharesTotal: $992,808.00 ($275.78/share)Burney Co.Bought 12,205 shares on 5/22/2024Ownership: 0.051%View All Insider TransactionsView All Institutional Transactions UTHR Stock Analysis - Frequently Asked Questions Should I buy or sell United Therapeutics stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" UTHR shares. View UTHR analyst ratings or view top-rated stocks. What is United Therapeutics' stock price target for 2024? 10 Wall Street analysts have issued 1 year target prices for United Therapeutics' stock. Their UTHR share price targets range from $240.00 to $400.00. On average, they anticipate the company's share price to reach $309.44 in the next twelve months. This suggests a possible upside of 12.5% from the stock's current price. View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts. How have UTHR shares performed in 2024? United Therapeutics' stock was trading at $219.89 at the beginning of 2024. Since then, UTHR stock has increased by 25.1% and is now trading at $275.13. View the best growth stocks for 2024 here. When is United Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our UTHR earnings forecast. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) issued its earnings results on Wednesday, May, 1st. The biotechnology company reported $6.17 EPS for the quarter, topping the consensus estimate of $5.63 by $0.54. The biotechnology company earned $677.70 million during the quarter, compared to the consensus estimate of $620.31 million. United Therapeutics had a net margin of 42.05% and a trailing twelve-month return on equity of 18.72%. The firm's revenue was up 33.7% on a year-over-year basis. During the same period in the prior year, the firm posted $4.86 EPS. What ETFs hold United Therapeutics' stock? ETFs with the largest weight of United Therapeutics (NASDAQ:UTHR) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Subversive Mental Health ETF (SANE), First Trust Nasdaq Pharmaceuticals ETF (FTXH), First Trust NYSE Arca Biotechnology Index Fund (FBT), Formidable Fortress ETF (KONG), Invesco Biotechnology & Genome ETF (PBE), Inspire Faithward Mid Cap Momentum ETF (GLRY) and First Trust Health Care AlphaDEX Fund (FXH). What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO? 64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE). Who are United Therapeutics' major shareholders? United Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.56%), Janus Henderson Group PLC (1.43%), Jane Street Group LLC (0.00%), LSV Asset Management (1.19%), Swedbank AB (0.95%) and Nordea Investment Management AB (0.68%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:UTHR) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & CompanyBiden replacement revealed?Paradigm PressThis unknown company solves the biggest issue with AIManward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
